Total Payments
$7,894
2024 Payments
$2,634
Companies
25
Transactions
309
Medicare Patients
2,926
Medicare Billing
$181,444
Payment Breakdown by Category
Food & Beverage$7,165 (90.8%)
Consulting$450.00 (5.7%)
Education$278.88 (3.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,165 | 304 | 90.8% |
| Consulting Fee | $450.00 | 1 | 5.7% |
| Education | $278.88 | 4 | 3.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $1,221 | 53 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $1,118 | 52 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $805.57 | 31 | $0 (2024) |
| ABBVIE INC. | $651.17 | 32 | $0 (2024) |
| LEO Pharma Inc. | $642.81 | 8 | $0 (2023) |
| Janssen Biotech, Inc. | $483.18 | 20 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $452.74 | 13 | $0 (2024) |
| Amgen Inc. | $449.72 | 19 | $0 (2024) |
| Lilly USA, LLC | $365.11 | 20 | $0 (2024) |
| Alkermes, Inc. | $353.07 | 3 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,634 | 119 | Janssen Biotech, Inc. ($323.41) |
| 2023 | $1,600 | 70 | Incyte Corporation ($435.82) |
| 2022 | $2,232 | 58 | LEO Pharma Inc. ($623.46) |
| 2021 | $1,428 | 62 | AbbVie Inc. ($374.12) |
All Payment Transactions
309 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $19.31 | General |
| Category: Dermatology | ||||||
| 12/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $4.35 | General |
| Category: Immunology | ||||||
| 12/19/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $0.84 | General |
| Category: Dermatology | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: Immunology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $5.81 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $15.72 | General |
| Category: Immunology | ||||||
| 11/26/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $16.83 | General |
| Category: Dermatology | ||||||
| 11/26/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $2.32 | General |
| Category: Dermatology | ||||||
| 11/21/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $17.91 | General |
| Category: Dermatology | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $12.69 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $34.46 | General |
| Category: Inflammation | ||||||
| 11/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $17.19 | General |
| Category: Immunology | ||||||
| 11/04/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $19.29 | General |
| Category: Dermatology | ||||||
| 11/04/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $0.43 | General |
| Category: Dermatology | ||||||
| 10/31/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $4.10 | General |
| Category: Immunology | ||||||
| 10/30/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: IMMUNOLOGY | ||||||
| 10/29/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: Immunology | ||||||
| 10/28/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $19.30 | General |
| Category: Obesity | ||||||
| 10/28/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Food and Beverage | In-kind items and services | $7.27 | General |
| Category: Immunology | ||||||
| 10/24/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: IMMUNOLOGY | ||||||
| 10/24/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $13.28 | General |
| Category: Dermatology | ||||||
| 10/22/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $19.32 | General |
| Category: IMMUNOLOGY | ||||||
| 10/08/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $16.15 | General |
| Category: Immunology | ||||||
| 10/03/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $31.68 | General |
| Category: Dermatology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 975 | 1,595 | $324,704 | $58,921 |
| 2022 | 15 | 1,032 | 1,587 | $345,481 | $63,954 |
| 2021 | 11 | 601 | 927 | $187,937 | $37,004 |
| 2020 | 7 | 318 | 459 | $109,266 | $21,566 |
Total Patients
2,926
Total Services
4,568
Medicare Billing
$181,444
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 216 | 286 | $75,133 | $13,359 | 17.8% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 151 | 195 | $64,167 | $11,849 | 18.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 80 | 138 | $51,365 | $9,798 | 19.1% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 79 | 88 | $25,973 | $4,605 | 17.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 108 | 152 | $29,660 | $4,429 | 14.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 116 | 134 | $22,008 | $4,344 | 19.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 48 | 48 | $15,640 | $2,925 | 18.7% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 11 | 12 | $10,646 | $2,221 | 20.9% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 70 | 425 | $8,257 | $1,615 | 19.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $8,718 | $1,263 | 14.5% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 22 | 31 | $4,539 | $1,029 | 22.7% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 24 | 24 | $5,051 | $954.82 | 18.9% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 16 | 18 | $2,988 | $509.85 | 17.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 16 | 26 | $560.00 | $19.36 | 3.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 222 | 299 | $79,530 | $14,710 | 18.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 158 | 208 | $68,914 | $13,530 | 19.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 100 | 133 | $49,853 | $10,060 | 20.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 77 | 89 | $26,804 | $4,659 | 17.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 121 | 153 | $29,936 | $4,130 | 13.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 65 | 65 | $21,281 | $3,714 | 17.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 88 | 103 | $16,955 | $3,288 | 19.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 34 | 34 | $16,646 | $2,769 | 16.6% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2022 | 11 | 11 | $9,886 | $2,129 | 21.5% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 80 | 396 | $7,736 | $1,609 | 20.8% |
| 17111 | Destruction of skin growth, 15 or more growths | Office | 2022 | 12 | 17 | $6,627 | $1,442 | 21.8% |
About Elvis Jacome, PA-C
Elvis Jacome, PA-C is a Physician Assistant healthcare provider based in El Paso, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/12/2007. The National Provider Identifier (NPI) number assigned to this provider is 1720138365.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Elvis Jacome, PA-C has received a total of $7,894 in payments from pharmaceutical and medical device companies, with $2,634 received in 2024. These payments were reported across 309 transactions from 25 companies. The most common payment nature is "Food and Beverage" ($7,165).
As a Medicare-enrolled provider, Jacome has provided services to 2,926 Medicare beneficiaries, totaling 4,568 services with total Medicare billing of $181,444. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Physician Assistant
- Other Specialties Physician Assistant
- Location El Paso, TX
- Active Since 01/12/2007
- Last Updated 02/15/2023
- Taxonomy Code 363A00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1720138365
Products in Payments
- OPZELURA (Drug) $1,087
- Sotyktu (Drug) $681.20
- ADBRY (Biological) $642.81
- ILUMYA (Biological) $567.47
- SKYRIZI (Biological) $446.40
- Otezla (Drug) $368.84
- TREMFYA (Drug) $323.41
- TALTZ (Drug) $315.38
- DUPIXENT (Biological) $307.53
- Winlevi (Drug) $260.36
- VTAMA (Drug) $254.96
- COSENTYX (Drug) $236.50
- ARISTADA (Drug) $229.20
- LIBTAYO (Biological) $176.25
- Bimzelx (Biological) $173.21
- Ilumya (Biological) $160.72
- REMICADE (Biological) $159.77
- HUMIRA (Biological) $159.02
- Zoryve (Drug) $152.15
- LYBALVI (Drug) $123.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Physician Assistant Doctors in El Paso
Javier Almeida, P.a.-C, P.A.-C
Physician Assistant — Payments: $19,908
Physician Assistant $19,908
Myrna Bejar, Pa, PA
Physician Assistant — Payments: $10,964
Physician Assistant $10,964
Damaris Rosado, Pa-C, PA-C
Physician Assistant — Payments: $6,826
Physician Assistant $6,826
Ryan Rodriguez, Pa-C, Atc, PA-C, ATC
Physician Assistant — Payments: $5,401
Physician Assistant $5,401
Clyde Morron, Pa, PA
Physician Assistant — Payments: $5,288
Physician Assistant $5,288
Mr. Felix Barron, Pa-C, PA-C
Physician Assistant — Payments: $5,225
Physician Assistant $5,225